We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Clorox (CLX) Up 2.6% Since the Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for The Clorox Company (CLX - Free Report) . Shares have added about 2.6% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Clorox Tops Earnings Estimate in Q3, Revises Guidance
Clorox released third-quarter fiscal 2017 results, wherein quarterly earnings from continuing operations of $1.31 per share jumped 8% year over year and surpassed the Zacks Consensus Estimate by a penny. Results gained from solid sales, reduced tax rate and gain from sale of a global facility (that forms part of the company’s Go Lean strategy). This was partly offset by higher advertising and promotional expenses, along with gross margin contraction.
Net sales of $1,477 million advanced nearly 3.6% year over year, falling slightly short of the Zacks Consensus Estimate of $1,479 million. This marked the company’s first sales miss after four consecutive beats.
During the quarter, gains from 7% volume growth, higher pricing at the International business and benefits from RenewLife (acquired in May 2016) were somewhat negated by unfavorable mix and greater trade promotional investments.
Clorox’s gross margin contracted 130 basis points (bps) to 44% in the quarter, owing to increase in manufacturing and logistics expenses, unfavorable mix, higher commodity expenses and increased trade promotion investments, somewhat compensated by efficient cost savings and improved pricing.
Revenue by Segment
Sales in the Cleaning segment improved 7% to $497 million, with a 13% rise in volumes. Volumes mainly gained from the strength in Home Care, particularly Clorox disinfecting wipes, along with strong volumes at the Professional Products’ cleaning brands.
Household sales grew 4% to $486 million, with volumes rising 9%. Volumes were mainly aided by the RenewLife acquisition and increased shipments at Cat Litter, somewhat offset by weak Charcoal shipments owing – partly accountable to unfavorable weather.
Sales at the Lifestyle segment fell 3% to $246 million, due to 1% dip in volumes, which in turn stemmed from reduced shipments at Water Filtration and Natural Personal Care.
In the International business segment, sales grew 3% to $248 million. However, volumes dropped 2%, mainly on account of softness in certain Latin American countries, especially Argentina. This was partly compensated by strength noted in Canada (including benefits from Renew Life’s buyout).
Financials
Clorox ended the quarter with cash and cash equivalents of $431 million, and long-term debt of $1,390 million. On a year-to-date basis, the company generated $483 million of net cash from continuing operations compared with $436 million in the year-ago period.
Looking Ahead
Clorox remains impressed with its sales and volume growth in the quarter, which was backed by robust innovations. Also, the company is on track with growth at its international business, and its Go Lean strategy. While the third quarter was marked by intense advertising and promotion investments to enhance brand value, it is likely to boost sales and volumes in fourth-quarter fiscal 2017. Also, the company envisions EBIT margin to improve in the fourth quarter backed by lower selling and administrative costs.
All said, management remains confident of delivering another year of top and bottom-line growth. However, currency is expected to have some adverse impact on the top line. Considering all factors, the company revised its fiscal 2017 outlook.
The company continues to expect fiscal 2017 sales growth in a range of 3–4%, driven by sales gains witnessed year to date, as well as nearly 2 points gains from the RenewLife buyout. This is expected to be partly offset by an adverse currency impact of 1 point.
Further, EBIT margin is now estimated to expand by 25 bps, compared to 25–50 bps forecasted earlier. This will be mainly backed by lower selling and administrative costs, as a percentage of sales, somewhat countered by reduced gross margin in fiscal 2017.
Finally, the company adjusted its earnings forecast for fiscal 2017 to $5.25–$5.35 per share from $5.23–$5.38 expected earlier. This reflects year-over-year growth of 7–9%. This forecast incorporates gains from strong year-to-date sales growth, product innovations and projections for EBIT margin expansion in the fiscal.
How Have Estimates Been Moving Since Then?
Following the release, investors have witnessed a downward trend in fresh estimates. There have been two revisions lower for the current quarter.
At this time, Clorox 's stock has a nice Growth Score of 'B', though it is lagging a lot on the momentum front with a 'D'. Following the exact same course, the stock was allocated also a grade of 'D' on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'D'. If you aren't focused on one strategy, this score is the one you should be interested in.
The company's stock is suitable solely for growth based on our styles scores.
Outlook
While estimates have been trending downward for the stock, the magnitude of these revisions have been net zero. Notably, the stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Clorox (CLX) Up 2.6% Since the Last Earnings Report?
It has been about a month since the last earnings report for The Clorox Company (CLX - Free Report) . Shares have added about 2.6% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Clorox Tops Earnings Estimate in Q3, Revises Guidance
Clorox released third-quarter fiscal 2017 results, wherein quarterly earnings from continuing operations of $1.31 per share jumped 8% year over year and surpassed the Zacks Consensus Estimate by a penny. Results gained from solid sales, reduced tax rate and gain from sale of a global facility (that forms part of the company’s Go Lean strategy). This was partly offset by higher advertising and promotional expenses, along with gross margin contraction.
Net sales of $1,477 million advanced nearly 3.6% year over year, falling slightly short of the Zacks Consensus Estimate of $1,479 million. This marked the company’s first sales miss after four consecutive beats.
During the quarter, gains from 7% volume growth, higher pricing at the International business and benefits from RenewLife (acquired in May 2016) were somewhat negated by unfavorable mix and greater trade promotional investments.
Clorox’s gross margin contracted 130 basis points (bps) to 44% in the quarter, owing to increase in manufacturing and logistics expenses, unfavorable mix, higher commodity expenses and increased trade promotion investments, somewhat compensated by efficient cost savings and improved pricing.
Revenue by Segment
Sales in the Cleaning segment improved 7% to $497 million, with a 13% rise in volumes. Volumes mainly gained from the strength in Home Care, particularly Clorox disinfecting wipes, along with strong volumes at the Professional Products’ cleaning brands.
Household sales grew 4% to $486 million, with volumes rising 9%. Volumes were mainly aided by the RenewLife acquisition and increased shipments at Cat Litter, somewhat offset by weak Charcoal shipments owing – partly accountable to unfavorable weather.
Sales at the Lifestyle segment fell 3% to $246 million, due to 1% dip in volumes, which in turn stemmed from reduced shipments at Water Filtration and Natural Personal Care.
In the International business segment, sales grew 3% to $248 million. However, volumes dropped 2%, mainly on account of softness in certain Latin American countries, especially Argentina. This was partly compensated by strength noted in Canada (including benefits from Renew Life’s buyout).
Financials
Clorox ended the quarter with cash and cash equivalents of $431 million, and long-term debt of $1,390 million. On a year-to-date basis, the company generated $483 million of net cash from continuing operations compared with $436 million in the year-ago period.
Looking Ahead
Clorox remains impressed with its sales and volume growth in the quarter, which was backed by robust innovations. Also, the company is on track with growth at its international business, and its Go Lean strategy. While the third quarter was marked by intense advertising and promotion investments to enhance brand value, it is likely to boost sales and volumes in fourth-quarter fiscal 2017. Also, the company envisions EBIT margin to improve in the fourth quarter backed by lower selling and administrative costs.
All said, management remains confident of delivering another year of top and bottom-line growth. However, currency is expected to have some adverse impact on the top line. Considering all factors, the company revised its fiscal 2017 outlook.
The company continues to expect fiscal 2017 sales growth in a range of 3–4%, driven by sales gains witnessed year to date, as well as nearly 2 points gains from the RenewLife buyout. This is expected to be partly offset by an adverse currency impact of 1 point.
Further, EBIT margin is now estimated to expand by 25 bps, compared to 25–50 bps forecasted earlier. This will be mainly backed by lower selling and administrative costs, as a percentage of sales, somewhat countered by reduced gross margin in fiscal 2017.
Finally, the company adjusted its earnings forecast for fiscal 2017 to $5.25–$5.35 per share from $5.23–$5.38 expected earlier. This reflects year-over-year growth of 7–9%. This forecast incorporates gains from strong year-to-date sales growth, product innovations and projections for EBIT margin expansion in the fiscal.
How Have Estimates Been Moving Since Then?
Following the release, investors have witnessed a downward trend in fresh estimates. There have been two revisions lower for the current quarter.
Clorox Company (The) Price and Consensus
Clorox Company (The) Price and Consensus | Clorox Company (The) Quote
VGM Scores
At this time, Clorox 's stock has a nice Growth Score of 'B', though it is lagging a lot on the momentum front with a 'D'. Following the exact same course, the stock was allocated also a grade of 'D' on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'D'. If you aren't focused on one strategy, this score is the one you should be interested in.
The company's stock is suitable solely for growth based on our styles scores.
Outlook
While estimates have been trending downward for the stock, the magnitude of these revisions have been net zero. Notably, the stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.